Toxicity and Tolerability of (177)Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study

Background: Peptide receptor radionuclide therapy (PRRT) has been recently approved for advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study reports the adverse events (AEs) observed with patient-tailored administered activity. Methods: Fifty-two PRRT naive patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatami, Alireza, Sistani, Golmehr, Sutherland, Duncan E. K., DeBrabandere, Sarah, Reid, Robert H., Laidley, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Organic Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900697/
https://www.ncbi.nlm.nih.gov/pubmed/35135467
http://dx.doi.org/10.2174/1874471014666210810100435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900697/
https://www.ncbi.nlm.nih.gov/pubmed/35135467
http://dx.doi.org/10.2174/1874471014666210810100435

Ejemplares similares